New results from one of the largest real-world evidence studies of chronic kidney disease (CKD) reveal the disease’s high burden on patients and health care systems, with disease prevalence estimated at 10% of the adult population. The results of the CArdioREnal and METabolic (CaReMe) CKD study are published today in: The Lancet Regional Health — Europe†
The multinational study of 2.4 million CKD patients in 9 countries in Europe, plus Israel and Canada, estimates the prevalence, outcomes and costs of CKD. Although CKD is estimated to be one of the most common diseases affecting one in ten adults, two out of three patients identified as having CKD in the study were found to be undiagnosed, putting them at high risk of morbidity and mortality and a high risk of mortality. significant burden on healthcare providers and systems.
Professor Navdeep Tangri, MD Ph.D., Department of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Canada, said: “To date, estimates of the prevalence, impact and cost of CKD have varied widely due to limited studies of the The CaReMe CKD study is one of the largest, longest and broadest studies assessing this chronic disease and adding to the body of evidence for CKD.The results highlight the significant impact of CKD on public health and the importance of early detection and disease management to improve patients’ lives and reduce healthcare costs.”
Alexander de Giorgio-Miller, Senior Vice President, Global Medical, AstraZeneca, said: “We know that there is still a significant unmet need for chronic kidney disease, with millions of patients yet to be diagnosed. Real-evidence studies such as these are critical to build our understanding of the gaps in diagnosis and clinical care pathways and to set ambitious quality standards to provide patients with better access to drugs that can prevent disease progression, disability and early death.”
CKD is a growing global health burden with an increasing contribution to overall mortality and significant financial costs and impact on healthcare providers. The study found that between 6-9% of patients with CKD die each year, and the leading cause of hospital visits and healthcare costs were CKD events and comorbidities like heart failure (HF). The impact of CKD is expected to increase in the coming years, with both the total number of CKD cases and the cost of managing CKD expected to increase further.
Johan Sundström et al, Prevalence, outcomes and costs of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: the CaReMe CKD study, The Lancet Regional Health — Europe (2022). DOI: 10.116/j.lanepe.2022.100438
Provided by AstraZeneca
Quote: New study indicates chronic kidney disease is present in one in ten adults (2022, June 30) retrieved July 1, 2022 from https://medicalxpress.com/news/2022-06-chronic-kidney-disease-ten- adults .html
This document is copyrighted. Other than fair dealing for personal study or research, nothing may be reproduced without written permission. The content is provided for informational purposes only.
#Study #Chronic #Kidney #Disease #Present #Ten #Adults